Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)
Primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. In most
 cases, platelet count is negatively correlated with the severity of bleeding. Correcting low
 platelets is the main measure to prevent bleeding in patients with ITP. Both rhTPO and
 eltrombopag act on TPO receptors to increase platelets.Which one will have a better
 short-term (2 weeks) effect to improve platelets is the purpose of the investigator's
 research.
Primary immune thrombocytopenia (ITP) is an acquired autoimmune hemorrhagic disease. ITP
 patients have an increased risk of bleeding and the clinical symptoms are petechia,
 ecchymosis, organ hemorrhage and even life-threatening bleeding. The mortality rate in ITP is
 increased approximately 60% compared with age- and sex matched comparisons, bleeding is one
 of the leading causes of death, thus treating and preventing bleeding is particularly
 important for those patients. In most cases, platelet count is negatively correlated with the
 severity of bleeding. Correcting low platelets is the main measure to prevent bleeding in
 patients with ITP. Recombinant human thrombopoietin (rhTPO), a full-length glycated TPO, is a
 recombinant form of c-Mpl ligand that competes with endogenous TPO for binding to TPO
 receptors (TPO-R, c-Mp0), many clinical trials have shown that rhTPO can efficiently and
 safely stimulate platelet production, increase peripheral blood platelet count. The State
 Food and Drug Administration approved the drug as the second-line treatment for patients with
 ITP in 2005. Eltrombopag is an oral, synthetic non-peptide small molecule human
 thrombopoietin receptor agonist approved by the US FDA in November 2008 for the treatment of
 patients with chronic ITP, which were inefficiently by use of glucocorticoids, immunoglobulin
 or splenectomy. However, pharmacokinetic study of eltrombopag showed that Asians have twice
 the drug exposure rate than non-Asians, so eltrombopag may have different effects in
 different populations. Therefore, this trial will compare the efficacy and safety of
 intravenous rhTPO or oral use of eltrombopag after 14 days of treatment in Chinese ITP
 patients.
Inclusion Criteria:

 1. The patient signs an informed consent form.

 2. Age from 18 to 75 years old

 3. The patient's first diagnosis of ITP is at least 6 months before enrollment; the
 platelet count must <30×109/L before taking the study drug (48 hours before).

 4. Patients who were diagnosed with ITP by bone marrow biopsy and other related
 examinations before enrollment(Bone marrow biopsy is valid for 30 days, including 30
 days);

 5. The patient has been treated with splenectomy for relapse or relapse; or the patient
 has not undergone splenectomy, but was ineffective or relapses after treatment with at
 least one first line drug. Past ITP therapy can include, but is not limited to,
 corticosteroids, immunoglobulins (IVIG or anti-D Immunoglobulin), azathioprine,
 danazol, cyclophosphamide and immunomodulators;

 6. Previous salvage treatments included infusion of platelets, immunoglobulins,
 immunomodulators, and cyclophosphamide must be completed 2 weeks prior to enrollment
 or treatment. Corticosteroids must end at least 14 days before enrollment.

 7. Patients receiving immunosuppressive agents (including corticosteroids, azathioprine,
 danazol, cyclosporin A, mycophenolate mofetil) or proprietary Chinese medicines have
 maintained a stable therapeutic dose for at least the last month; patients who
 received rituximab should be discontinued half a year prior to enrollment; patients
 with spleen were enrolled six months after surgery;

 8. No heart disease in the past 3 months, including NYHA grade III/IV charge

 , heart failure, arrhythmia or myocardial infarction requiring medical treatment;

 9. Laboratory tests for coagulation function showed that prothrombin time (PT/INR) and
 activated partial thromboplastin time (APTT) values did not exceed 20% of the normal
 reference range.No history of coagulation abnormalities except ITP;

 10. White blood cell count, neutrophil absolute value, hemoglobin in the normal
 value.Except in the following cases: a) Platelet count <30×10^9/L within Day1 or Day1
 within 48 hours; b) Hemoglobin: if anemia is clearly caused by ITP (thrombocytopenia
 caused blood loss), the lower limit of the subject's hemoglobin level below the normal
 value can be based on the investigator's judgment to decide the subject whether to be
 selected; c) absolute neutrophil count ≥ 1.5 × 109 / L can be enrolled;

 11. The following clinical biochemical indicators must be within 20% of the normal range:
 creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin and
 alkaline phosphatase. In addition, serum albumin is not lower than the lower limit of
 normal value by 10%;

 12. Subjects took an approved method of contraception. Female subjects (or female partners
 of male subjects) must be infertile (hysterectomy, bilateral salpingectomy, bilateral
 tubal ligation or more than 1 year after menopause) or have fertility but before the
 first dose for 2 weeks, study-approved contraceptive methods were used throughout the
 study period to 28 days after the end of the study or discontinuation of the
 study.Male subjects with a fertile female partner must have undergone vasectomy or
 consent to effective contraception throughout the study period (2 weeks prior to the
 first dose, throughout the study period, until the end of the study or 28 days after
 the discontinuation of the study) method;

 13. Women with fertility must have a negative serum pregnancy test within 24 hours prior
 to the first dose;

 14. Subjects fully understand and are able to comply with the requirements of the research
 protocol and are willing to complete the study as planned.

 Exclusion Criteria:

 1. Subjects had a history of any arterial/venous thrombosis (including stroke, transient
 ischemic attack, myocardial infarction, deep vein thrombosis, or pulmonary embolism)
 and had at least 2 of the following risk factors: hormone replacement therapy, oral
 contraception medicine (including estrogen), smoking, diabetes, hypercholesterolemia,
 drug-controlled hypertension, malignant tumors, hereditary coagulopathy;

 2. Abnormalities other than ITP during the screening phase or any medical history or
 condition that the investigator considered unsuitable for participation in the study;

 3. Patients with BMI ≥ 28;

 4. Pregnant or lactating women;

 5. A history of alcohol/drug abuse within 12 months prior to screening or first dose;

 6. Previous treatment with a specific study drug other than rhTPO or other research
 treatments;

 7. The subject has previously received or is currently receiving treatment with exenatide
 or other thrombopoietin receptor agonists;

 8. Throughout the study, medications that affected platelet function (including but not
 limited to aspirin, clopidogrel and/or non-steroidal anti-inflammatory drugs NSAIDs)
 or anticoagulant therapy were continued for >3 days;

 9. Accept any herbal or nutritional supplements, excluding vitamin supplements and
 mineral supplements within 1 week prior to the start of the study;

 10. There is a history of abnormal platelet aggregation that may affect the reliability of
 platelet count measurements;

 11. Before the first dose administration, the bone marrow biopsy showed abnormality except
 for ITP within 4 weeks, and the investigator judged that the abnormality made the
 subject unsuitable for the study, or the bone marrow biopsy showed other primary
 disease which caused thrombocytopenia;

 12. Evidence of all laboratory or clinical HIV infections, previous clinical history of
 hepatitis C,hepatitis B, or active hepatitis at screening. Laboratory tests during the
 screening period indicate hepatitis C infection or hepatitis B infection. (Defined as
 HBsAg test positive, in addition, if the HBsAg test is negative, but HBcAb is
 positive, regardless of the status of HBsAb, HBV DNA testing is required, if positive,
 subjects should be excluded);

 13. Rescuing treatment is required before the first dose of the drug.